MedTrace Logo

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

NCT05457049 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2022-09-29

No results posted yet for this study

Summary

Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

Molecular residual disease test

OncoMRD Lung

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-01
Completion
2025-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05457049 on ClinicalTrials.gov